Acer Therapeutics Inc

NASDAQ:ACER  
2.83
-0.09 (-3.08%)
Products

Acer Therapeutics Plans Clinical Trial For Edsivo™ (Celiprolol) Following Type B FDA Meeting

Published: 06/10/2021 12:46 GMT
Acer Therapeutics Inc (ACER) - Acer Therapeutics Plans Clinical Trial for Edsivo™ (celiprolol) Following Type B FDA Meeting.
Acer Therapeutics - in Second Half of 2021, Co Intends to Submit a Protocol for Prospective Study, Along With Ind for Edsivo.
Acer Therapeutics Inc - Phase 3 Clinical Trial for Edsivo Estimated to Take About 3.5 Years to Complete Once Fully Enrolled.
Acer Therapeutics - in H2 2021, Co Will Request Breakthrough Therapy Designation, Coordinate With FDA to Reach Agreement on Spa for Edsivo.